List of Excipients in Branded Drug SUCRAID

Last updated: July 28, 2026

SUCRAID (sucraid) Excipient Strategy and Commercial Opportunities: What formulation choices expand patent and manufacturing optionality?

SUCRAID (sacrosidase; marketed as SUCRAID by specialty pharma for congenital sucrase-isomaltase deficiency, CSID) sits in a small-label specialty category where formulation design can materially affect manufacturability, taste/masking, stability, and route-to-market economics. For commercial opportunity, the highest value excipient strategy is the one that (1) preserves or improves physical stability across intended shelf life, (2) reduces variability in viscosity and flow for dose-volume accuracy, and (3) enables defensible formulation IP positioning around the oral liquid product performance target, not just the API.

What excipients matter most for SUCRAID oral liquid performance?

SUCRAID is an oral liquid for pediatric and adult CSID patients. In practical formulation terms, the excipient stack must address three recurring pain points for enzyme therapeutics in aqueous oral dosage forms: (1) enzymatic activity loss driven by pH, temperature, and interfacial stress; (2) physical stability (viscosity changes, precipitation, foaming); (3) palatability and dosing compliance (taste, mouthfeel, gag risk in children).

pH control and buffer system

• Enzymatic activity and chemical stability of sacrosidase are pH sensitive. A buffering system that holds pH across temperature excursions reduces activity drift and slows degradation pathways.
• Commercial risk: buffer capacity exhaustion can accelerate activity loss near end of shelf life if ionic strength or CO2 uptake shifts system pH.

Excipient strategy

• Target a buffer with strong capacity in the working pH window, compatible with oral ingestion and downstream packaging (plastic vs glass).
• Use low-reactivity excipients to reduce oxidative or hydrolytic stress.

Stabilizing agents to protect enzyme activity

For oral enzyme liquids, excipient selection typically addresses:

• Protein stabilization against aggregation
• Protection against autolysis or chemical degradation
• Reduction in surface adsorption to container headspace and interfaces

Excipient strategy

• Choose stabilizers that reduce aggregation and preserve activity under storage and during dispensing.
• Minimize excipients that catalyze oxidation or accelerate Maillard-type side reactions when sugar alcohols or reducing components are present (if used).

Tonicity adjusters and osmolality

Oral enzyme liquids often include tonicity agents to reduce GI irritation and improve tolerability.

• Commercial benefit: tighter tolerability improves persistence in chronic use profiles (CSID is long term).

Excipient strategy

• Use tonicity agents that maintain osmolality within tolerability thresholds and do not destabilize the enzyme.

Viscosity modifiers for dosing accuracy

Dose-by-volume accuracy is critical for enzyme products dosed multiple times daily, including for children.

• Commercial risk: viscosity changes affect dropper calibration, pipetting reproducibility, and patient adherence.

Excipient strategy

• Stabilize viscosity over temperature and time to protect dosing uniformity.
• Prefer viscosity excipients that do not form gels, do not precipitate, and remain compatible with the closure system.

Taste masking and palatability

CSID patients, particularly pediatric, face compliance challenges. Flavor systems and sweetness agents can be decisive.

Excipient strategy

• Use taste-masking approaches that do not destabilize the enzyme, such as encapsulated flavors, controlled release flavors, or sweeteners that are stable and compatible with protein formulations.
• Maintain mouthfeel consistency to reduce aversion.

Preservatives and microbial control

If SUCRAID product presentation requires antimicrobial preservation (depending on manufacturing, container closure integrity, and whether it is single-use), preservative selection matters.

• Commercial risk: wrong preservative can reduce enzymatic activity, catalyze degradation, or affect palatability.

Excipient strategy

• Use preservative systems that preserve enzyme activity while achieving microbial risk control for multi-dose distribution.

How can excipient reformulation expand SUCRAID commercial opportunities without triggering major clinical/regulatory risk?

Commercial opportunity from excipient strategy is usually two-track: (1) manufacturing and cost-of-goods (COGS) optimization; (2) “performance-for-patient” improvements that reduce returns, complaints, and adherence losses.

Opportunity 1: Shelf-life extension and activity retention improvements

The highest-value improvement in enzyme liquids is increasing the time window where enzyme activity is maintained.

• Outcome metrics to target: assay potency at end of shelf life; activity retention after excursions; viscosity consistency; pH stability.

Commercial impact

• Longer shelf-life increases distributor confidence and reduces inventory obsolescence.
• Better end-of-shelf-life potency increases payer and provider confidence.

Execution via excipients

• Optimize buffer capacity and stabilizer selection to reduce activity decline under long-term storage.
• Improve packaging-excipient compatibility to reduce adsorption losses.

Opportunity 2: Manufacturing robustness and reduced batch variability

COGS and supply continuity drive specialty pharma competitiveness more than raw formulation complexity.

• Excipient selection can reduce shear sensitivity during mixing and improve fill performance.

Execution via excipients

• Select excipients with reproducible viscosity and particle behavior across lots.
• Use excipients that dissolve consistently and reduce foaming or incomplete dispersion.

Opportunity 3: Easier dosing and better adherence

Dosing accuracy and palatability can translate into measurable adherence improvement.

• Enzyme products are chronically dosed; small dosing friction creates cumulative adherence loss.

Execution via excipients

• Improve viscosity and dropper flow characteristics.
• Reduce bitterness and aftertaste through compatible taste system changes.

Opportunity 4: Lower cost excipient sourcing

Specialty manufacturing is sensitive to supply chain disruptions.

• Replacing scarce excipients with functionally equivalent excipients can reduce cost volatility.

Execution via excipients

• Use alternative grades with equivalent specs for viscosity/purity.
• Align supplier qualification strategy to stability targets.

Which excipient categories are most likely to be patent-relevant for SUCRAID?

Excipient strategy can be patent-relevant when the formulation as a whole creates a novel property profile or when the patent claims combinations tied to measurable performance.

Patent-relevant combination patterns

Common claimable patterns for oral liquid enzyme formulations include:

• Defined buffer pH plus specific stabilizer classes at specified concentration ranges
• Specific viscosity modifier systems to achieve dosing and stability properties
• Stabilizer plus preservative combinations that preserve enzyme activity
• Taste masking systems that meet palatability targets without compromising potency

How to think about “defensibility” in excipient IP

To create a commercial wedge, an excipient reformulation should produce:

• A measurable potency retention improvement (assay-based)
• A measurable physical stability improvement (e.g., no precipitation, stable viscosity)
• Improved dosing performance (dispensing accuracy and flow)
• A tolerability/palatability profile (patient acceptance data)

What formulation patents typically protect oral liquid enzyme drugs like SUCRAID?

For enzyme oral liquid drugs, patent protection commonly spans:

• Composition of matter for the drug product (broad “formulation” claims)
• Specific excipient compositions with concentration ranges
• Manufacturing processes controlling stability
• Packaging-related stability protection (sometimes indirectly through process constraints)

Formulation patent targets for an excipient strategy

• Buffer system and pH window
• Stabilizer type and concentration
• Viscosity modifier and rheology targets
• Preservative system and compatibility
• Optional flavor/taste components with stability constraints
• Container-closure system compatibility

When does SUCRAID lose exclusivity, and what role do excipient-only changes play in generic entry risk?

This requires mapping SUCRAID’s approved NDA/Orange Book patents and exclusivity periods. Without the Orange Book listing set and current status for SUCRAID in the US, any “expiration” or “entry risk” statement would be incomplete.

No release-ready exclusivity timeline can be produced here without the Orange Book patent table and expiration data for SUCRAID’s specific US approval and listed patents.

What is the Orange Book status of SUCRAID, and which listed patents are excipient-sensitive?

A complete and accurate Orange Book mapping requires the specific US application identifier, listed patent numbers, and their claim scope. That dataset is not present in the prompt.

No Orange Book status or patent-to-excipient claim sensitivity mapping can be produced here.

What paragraph IV and litigation risks exist for SUCRAID generic competitors?

A paragraph IV risk assessment requires:

• The Orange Book patent list
• Any ANDA filings referencing SUCRAID
• Known litigation dockets (settlement terms, triggers, 30-month stays)
• Whether challenges target composition claims, method claims, or formulation/performance claims

No litigation or paragraph IV risk can be stated accurately without the ANDA/Orange Book/litigation record.

How do excipients affect bioequivalence and clinical bridging for SUCRAID-related reformulations?

For oral enzyme drugs, excipient changes can trigger:

• Different in vivo release behavior (GI conditions interact with buffer and viscosity systems)
• Different GI tolerability influencing absorption indirectly
• Different enzyme stability in gastric/intestinal transit affecting activity and pharmacodynamics

Excipient-specific levers

• Buffer: changes microenvironment pH at administration and during early GI transit
• Viscosity: affects gastric emptying dynamics and distribution
• Preservatives/surfactants (if used): can impact mucosal interactions and enzyme survival

Commercial implication

• Reformulations with functional equivalence can be positioned for reduced bridging burden, but any claim-ready filing pathway depends on regulatory review of the actual differences.

Which excipient strategies improve manufacturing and supply continuity for SUCRAID oral liquid?

Fill-finish compatibility

• Closure leachables and adsorption effects can reduce enzymatic activity.
• Packaging transitions (glass to plastic or vice versa) can require excipient re-optimization.

Strategy

• Validate compatibility of stabilizer system with the intended closure and liner materials.
• Reduce surfactants or agents that increase adsorption losses if they are unnecessary.

Viscosity and pumpability

• Dropper and pump systems need stable rheology to preserve patient dose accuracy.
• Batch-to-batch viscosity shifts can increase complaint rates.

Strategy

• Use viscosity systems with high tolerance to temperature and shear.
• Define mixing and hold-time controls to keep the enzyme stable.

Stability under transit and excursions

• Distribution includes temperature and vibration stress.
• Excipient systems can buffer against these stresses.

Strategy

• Optimize thermal protection through stabilizers and buffer capacity.
• Improve resistance to interfacial stress during agitation and filling.

Formulation and commercial opportunity map: what should a “next-gen” SUCRAID line target with excipients?

Opportunity	Excipient design target	Product outcome	Commercial value
Shelf-life gain	Strong buffer capacity + enzyme stabilizer that reduces activity drift	Higher potency at end-of-shelf-life	Lower inventory obsolescence; higher payer confidence
Robust dosing	Stable viscosity and flow through closure	Better dose accuracy and fewer dosing complaints	Improved adherence; reduced returns
Compliance improvement	Taste masking system compatible with enzyme stability	Better patient acceptance	Higher persistence in chronic use
Cost and supply	Alternative excipients with equivalent specs	Lower COGS volatility	Supply continuity and margin protection
Manufacturing speed	Excipients that dissolve/disperse consistently	Reduced batch failures	Higher manufacturing throughput

How does SUCRAID compare with competing therapies in excipient and formulation priorities?

In CSID, competing options are limited, but the formulation challenge profile is consistent across oral specialty enzyme products:

• Stabilize enzyme activity over shelf life
• Maintain dosing accuracy via viscosity control
• Protect against microbial risk and taste-driven nonadherence

Key difference

• Competitors that offer alternative delivery systems (capsules, powders, or different liquid rheology) may change excipient priorities. Without named competitors and their formulation specs, a concrete comparative excipient ranking cannot be produced.

Key Takeaways

• The highest-leverage excipient strategy for SUCRAID oral liquid is pH/buffer and enzyme stabilization paired with viscosity control to protect potency and dose accuracy over time.
• Palatability and dosing ease are commercial levers that can reduce adherence friction in chronic CSID use.
• Patent and competitive defensibility generally emerges from excipient combinations tied to measurable performance targets: potency retention, physical stability, and dispensing behavior.
• Orange Book status, exclusivity timelines, and litigation risk require SUCRAID’s specific US Orange Book listing set and ANDA/lawsuit record, which are not contained in the prompt.

FAQs

1. What excipient changes most commonly impact enzyme activity in oral liquid formulations?
2. How do buffer and viscosity choices affect shelf-life potency and dosing accuracy for oral enzymes?
3. What formulation performance data best supports excipient-driven differentiation for specialty oral liquids?
4. How do preservatives influence enzyme stability and patient tolerability in multi-dose oral liquids?
5. What manufacturing tests best de-risk fill-finish and container-closure compatibility for enzyme liquids?

References (APA)

1. No sources were provided in the prompt.